Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers August 22, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - August 22, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/22/17 - $889.3 mn for Global Contrast Injector Market by 2022
Zion Market Research has published a new report titled "Contrast Injector Market by Product (Injector Systems, Consumables, Accessories), & Application (Radiology, Interventional Cardiology, Interventional Radiology) - Global Indust...
8/22/17 - ABPI - Life Sciences leaders respond to latest Brexit position paper
Release date- 21082017- The Association of the British Pharmaceutical Industry and the BioIndustry Association have welcomed the publication of' Continuity in the availability of goods for the EU and the UK', published today by the UK Government's Department for Exiting the European Union. The paper outlines a range of principles' to ensure that go
8/22/17 - AEPP Announces Proposed Name Change to Oncolix, Inc.
AEPP, a Houston- based biotechnology company focused on gynecological cancers, today announced it intends to change its name to Oncolix, Inc. The new name is expected to be effective after the mailing of notice to its shareholders in September. AEPP recently acquired all of the outstanding securities of Oncolix, Inc. in a reverse merger completed
8/22/17 - Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Agile Therapeutics, Inc. a women s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO will present at the Rodman& Renshaw 19 th Annual Global Investment Conference on Tuesday, September 12, 2017 at 9:10 AM ET in New York.. To access the live and archived webcasts of the presentation, visit the Investor
8/22/17 - AKCDA plans to form manufacturing company to invest in pharma park as a manufacturer [Sport360]
Supporting the governments move to set up a pharma park in the state, the All Kerala Chemists& Druggists Association, the pharma trade body in Kerala, plans to foray into manufacturing sector shortly. As far as the Kerala based pharma SSI units are concerned, they are all financially weak and unable to invest much for the project. For their surviva
8/22/17 - ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada [T-break Tech (Middle East)]
The FDA has today transferred the US product licences for the SLIT-tablet portfolio to ALK allowing the company to give full speed on the US activities. ALK plans to expand pivotal Phase III clinical trial on allergic asthma to include US patients based on discussions with the FDA. Full-year financial guidance for operating profit has been revised
8/22/17 - Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
Release date- 21082017- DUBLIN- Alkermes plc today announced the initiation of its rolling submission of a New Drug Application to the U.S. Food and Drug Administration, seeking marketing approval of ALKS 5461, a once daily, oral investigational medicine with a novel mechanism of action, for the adjunctive treatment of major depressive disorder.
8/22/17 - Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer
The Alliance Foundation Trials, LLC, in conjunction with Pfizer and six international cancer research groups, today announced the launch of PATINA a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/ 6 inhibitor palbociclib. The PATINA trial offers an exciting opportunity for a new global collaborative initiative
8/22/17 - ALP Nutrition Products Now Available on Multiple Online Retail Sites [Algeria Press Service]
-ALP Nutrition, a company based in Germany that creates a variety of high-quality liquid food supplements, is pushing its marketing strategy by making its products available on a wide range of popular sites. Its products are available both on major retail platforms and specialty nutritional supplement sites like,,...
Release date- 21082017- GAITHERSBURG, Md.- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug application to the U.S Food and Drug Administration for NasoVAX, the Company's intranasally administered recombinant flu vaccine. Sybil Tasker, Chief Medical Officer at Altimm
8/22/17 - Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial [Syrian Arab News Agency]
Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug application to the U.S Food and Drug Administration for NasoVAX, the Companys intranasally administered recombinant flu vaccine. Sybil Tasker, Chief Medical Officer at Altimmune. Current vaccines leave significant room
8/22/17 - American Lung Association Names 2017-2018 Volunteer Spokespeople
The American Lung Association issued the following news release:. Serving as the nation's premiere resource for lung health, the American Lung Association has expanded its network of expert resources available to the news media through the fiscal year 2018 National Volunteer Spokesperson program. The American Lung Association's 2017-2018 volunteer.
8/22/17 - Analysis on Implantable Drug Delivery Devices Market Report Upto 2023
The new research report on Implantable Drug Delivery Devices Market offered by provides Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016-2023. The global implantable drug delivery devices market research r...
8/22/17 - Antimicrobial Coatings Market to Gain From Increasing Need of Hygiene in Various Industries From 2014 to 2025: Million Insights
The global antimicrobial coating market was worth USD 2.44 billion in 2015. Indian pharmaceutical companies are driving into antimicrobial market to be in line with the regulatory standards. The effect of micro-organisms on people improves health concerns owing to boost the market over the forecast period.
8/22/17 - APNewsBreak: Utah to obey order for DEA drug database search
Utah will obey a court order to let the U.S. Drug Enforcement Administration search a prescription-drug database without a warrant, despite a state law designed to protect patient privacy. A federal appeals court also sided with the DEA in a case involving subpoenas of Oregon's prescription-drug database. The DEA fought to be exempt from the law
8/22/17 - Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress [T-break Tech (Middle East)]
-Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, today announced that an interim analysis of data from the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of...
8/22/17 - Astellas Pharma Inc. - First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy
Release date- 21082017- TOKYO- Astellas Pharma Inc. announced today that the first patient was dosed in the registrational Phase 3 MORPHO trial of gilteritinib, the fourth Phase 3 trial underway in the gilteritinib clinical development program. 'We know that FLT3+ AML patients face potentially worse outcomes than those with other mutations, and whi
8/22/17 - AstraZeneca plc. (ADR)(NYSE:AZN) Invests $29.5 Million In Ethris For mRNA-based Therapies Development
AstraZeneca plc. (ADR)(NYSE:AZN) has inked a strategic collaboration agreement with Ethris for the development of mRNA-based respiratory disease therapies. The five-year strategic collaboration seeks to leverage Ethris proprietary Stabilized Non-Immunogenic mRNA technology. AstraZeneca-Ethris Collaboration Under the terms of the agreement, Ethris i
8/22/17 - Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer
Atara Biotherapeutics, Inc., a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis, today announced the appointment of Kanya Rajangam, M.D., Ph.D., as Senior Vice President and Chief Medical Officer. Kanya has an exemplary track record leading clinical development and
8/22/17 - Aurobindo Pharma gets USFDA nod for anti-HIV drug [Arab News (Saudi Arabia)]
Aurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, used for the treatment of HIV, in the US market. In a BSE filing, Aurobindo Pharma said it has received "tentative approval from the US Food and Drug Administration under the US President`s Emergency Plan For AIDS
8/22/17 - BCC to Enter Into Joint Venture With Israeli Pharmaceutical Company Panaxia
The Canadian Bioceutical Corporation today announced the signing of a Term Sheet outlining the binding conditions under which it will enter into a Joint Venture agreement with Panaxia Pharmaceutical Industries Ltd.. Under the terms of the agreement, Panaxia will be providing proprietary, smokeless, pharma-grade cannabis-based products that have b
8/22/17 - BESPONSA (inotuzumab ozogamicin) Approved for Treatment of Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia, Available for Order at Biologics, Inc.
Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA , a promising new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approved by the U.S. Food and Drug Adminis
8/22/17 - Bio Pharma Buffer 2017 Global Market Outlook,Research,Trends and Forecast to 2022
This report studies the Bio Pharma Buffer market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Bio Pharma Buffer market by product type and applications/end industries. The Asia-Pacific will oc
8/22/17 - BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
Release date- 21082017- Tel Aviv, Israel- BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL8040 for the mobilization of hematopoietic stem cells for autologous...
8/22/17 - BUYINS.NET: BUYINS.NET: CVS SqueezeTrigger Price is $77.87. There is $2,014,110,743 That Short Sellers Still Need To Cover.
BUYINS.NET/ is monitoring CVS Caremark Corp in real time and just received an alert that CVS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 3,052,945,503 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $77.87. From August 2012 t
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement